Cross-Sector entity
Of the tracked stories, 2 of 2 also mention Boston Scientific, the most common co-covered peer. The clearest coverage concentration is health-it: 1 of 2 stories, with the rest divided among 1 other category. Biote appears in 2 tracked Cross-Sector stories from March 12, 2026.
2 verified stories tracked
Last mentioned: Mar 12, 2026
Entity pulse
Coverage balance Positive coverage leads. Positive coverage exceeds negative coverage by 100 percentage points.
Figures are computed live from our source-verified story record — see our methodology for how impact and sentiment are derived.
Of the tracked stories, 2 of 2 also mention Boston Scientific, the most common co-covered peer. The clearest coverage concentration is health-it: 1 of 2 stories, with the rest divided among 1 other category. Biote appears in 2 tracked Cross-Sector stories from March 12, 2026. The tracked stories average 9 original sources each.
Computed from the 2 stories linked to this entity. Beat comparisons are omitted because no baseline was available for this window.
Coverage cohort
Other entities that clear the same relevance threshold in stories also covering Biote. Shared-story counts are live from our verified record — not editorial picks.
NXT 41X Launch
Anticipated commercial launch of Elutia's next-gen drug-eluting biomaterial.
Bumble 2.0 Launch
Targeted launch of AI-enabled platform experience.
Codexis CDMO Expansion
Announced three major CDMO agreements with Bachem, Nitto Avecia, and Axolabs.
Elutia FDA Milestone
Expected FDA submission for NXT 41X product line.
Elutia Divestiture
Completed $88M sale of bioenvelope business to Boston Scientific.
Q4 2025 earnings for specialized biotech firms reveal a sector-wide shift toward high-margin manufacturing and strategic divestitures. While Codexis capitalizes on its Merck partnership and ECOsynthesis platform, Elutia has cleared its debt through an $88 million divestiture to Boston Scientific.
The Q4 2025 earnings cycle for mid-cap healthcare and life sciences firms reveals a strategic shift toward high-margin AI integration and portfolio streamlining. Companies like Elutia and Codexis are leveraging divestitures and technology transfers to shore up balance sheets, while AI-driven productivity gains are becoming a primary differentiator in clinical and operational workflows.
